Gainers

• Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million.
• Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 82.79% to $3.4. The market value of their outstanding shares is at $3.2 million.
• Rani Therapeutics Hldgs (NASDAQ:RANI) shares increased by 25.87% to $0.87. The company's market cap stands at $77.6 million.
• Arrowhead Pharma (NASDAQ:ARWR) shares rose 21.39% to $90.46. The company's market cap stands at $10.4 billion.
• InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 13.63% to $1.75. The company's market cap stands at $8.2 million.
• Processa Pharma (NASDAQ:PCSA) shares moved upwards by 11.61% to $2.5. The company's market cap stands at $6.2 million.

Losers

• China Pharma Holding (AMEX:CPHI) shares fell 77.3% to $1.84 during Wednesday's regular session. The market value of their outstanding shares is at $328.2 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) stock declined by 49.3% to $1.45. The market value of their outstanding shares is at $135.0 million.
• Picard Medical (AMEX:PMI) stock decreased by 27.07% to $0.09. The company's market cap stands at $12.3 million.
• Axe Compute (NASDAQ:AGPU) shares fell 26.73% to $6.99. The market value of their outstanding shares is at $108.6 million.
• QTREX Quantum (NASDAQ:QTEX) shares decreased by 24.74% to $0.89. The market value of their outstanding shares is at $65.7 million.
• Catheter Precision (AMEX:VTAK) stock decreased by 23.07% to $0.38. The company's market cap stands at $1.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.